• E-mail
  • Save
75 Stories on Schering-Plough Corporation
Search this topic

Probe widens on Vytorin safety

A House committee investigating the safety and effectiveness of the popular cholesterol drug Vytorin and one of its components is turning up the heat on the drug's makers.

CNNMoney: Stocks shake off jobs, GM

U.S. stock futures rebounded Friday following a better-than-expected July employment report and even as General Motors booked a nearly $16 billion loss.

CNNMoney: Stocks retreat slightly

Stocks closed modestly lower Monday, as rising oil prices and concerns in the tech and drug sectors overpowered a better-than-expected earnings report from Bank of America.

CNNMoney: Stocks poised to rally

Stock futures climbed Monday morning as investors cheered better-than-expected earnings from Bank of America and the announcement of a deal between Yahoo and activist investor Carl Icahn.

CNNMoney: Stocks inch higher

Stocks inched higher Thursday, as investors continued to bet that the worst of the credit crisis is behind the market. However, gains were limited by some jitters ahead of Friday's big monthly jobs report.

CNNMoney: Stocks up day, down quarter

Falling oil prices helped lift stocks Monday, at the end of an otherwise abysmal quarter on Wall Street, marred by fears of a recession amid the housing crisis and credit market fallout.

CNNMoney: Big Pharma opens wallet to Dems

Democrats have long served as the traditional enemy of Big Pharma, but in this presidential campaign, the left is taking the lion's share of drugmaker money.

Fortune: Cholesterol skeptics have their day

Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.

Time.com: Is Vytorin a Failure?

Surprising study results show that the popular heart drug doesn't live up to its claims -- and three new trials are now under way

CNNMoney: Techs advance after selloff

Tech stocks held on to gains Monday afternoon, near the end of a choppy session, but the broader market was mixed as investors remained wary after last week's big selloff.

Advertisement
Quick Job Search :
keyword(s):
enter city:
Home  |  World  |  U.S.  |  Politics  |  Crime  |  Entertainment  |  Health  |  Tech  |  Travel  |  Living  |  Business  |  Sports  |  Time.com
Podcasts  |  Blogs  |  CNN Mobile  |  Preferences  |  Email Alerts  |  CNN Radio  |  CNN Shop  |  Site Map
© 2008 Cable News Network. A Time Warner Company. All Rights Reserved.